BioNTech SE (BNTX) AI Stock Analysis

• Market Cap: $27.72B
• Dividend Yield: N/A
• Average Volume (3M): 630.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: 0.58%
• EPS Growth: -764.64%
• Country: US
• Employees: 6,772
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -2.03
• Shares Outstanding: 246,236,000
• 10 Day Avg. Volume: 581,433
• 30 Day Avg. Volume: 630,363
• PEG Ratio: 1.96
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $138.59
• Price Target Upside: 20.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 19

• Rating: 62 Neutral
• Price Target: $122.00 ▲(5.80%Upside)

BioNTech's overall stock score is primarily influenced by its strong technical indicators and robust balance sheet. However, its valuation is hampered by unprofitability, and financial performance concerns due to declining revenues and high costs. The earnings call highlights strategic advancements but also underscores financial challenges.

Positive Factors

Manufacturing Expansion

The acquisition expands BioNTech's manufacturing capability due to CureVac's state-of-the-art research and manufacturing site in Tübingen.

Regulatory Approval

BioNTech SE has been granted Orphan Drug Designation for a recombinant bispecific antibody for the treatment of small cell lung cancer, providing for seven years of market exclusivity post-approval.

Strategic Acquisition

The acquisition of CureVac by BioNTech is viewed as a strategic move to eliminate legal and financial uncertainties related to ongoing litigation over mRNA intellectual property.

Negative Factors

Clinical Data Risks

Risks include negative data for BNT122, BNT111, BNT113, BNT116, BNT211, BNT316, BNT323, and BNT327.

Market Uptake Concerns

Risks include slower-than-expected market uptake and failure to advance other programs in a timely manner.

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes Money

BioNTech makes money primarily through the development and commercialization of its mRNA-based therapies and vaccines. A significant portion of its revenue comes from its COVID-19 vaccine, Comirnaty, which was developed in partnership with Pfizer. This partnership involves a profit-sharing agreement where BioNTech receives a share of the revenue generated from the vaccine sales. Additionally, BioNTech earns revenue through collaborations and licensing agreements with other pharmaceutical companies, governments, and health organizations, which may include milestone payments, royalties, and research funding. The company also invests in the development of other therapeutic areas, such as oncology, which could become future revenue streams as these products reach commercialization.

BioNTech SE Financial Statement Overview

Summary

BioNTech's financial performance presents a mixed picture. While the company boasts a strong balance sheet with a favorable debt-to-equity ratio, indicating financial stability, the income and cash flow statements reveal challenges such as negative net margins and volatile cash flow trends. These issues highlight operational inefficiencies and cash management concerns that need addressing.

Income Statement

BioNTech's income statement reflects significant challenges in profitability. Recent TTM figures show negative net and EBIT margins, indicating operational inefficiencies. Although the company had strong revenue in previous years, recent declines highlight potential revenue instability.

Balance Sheet

BioNTech's balance sheet is robust, with a strong equity base and low levels of debt, resulting in a favorable debt-to-equity ratio. The equity ratio remains solid, underscoring financial stability. However, recent trends in reduced stockholders' equity warrant caution.

Cash Flow

The cash flow analysis reveals a volatile free cash flow trend, with recent TTM figures showing a significant decline. While operating cash flow remains positive, the substantial drop in free cash flow raises concerns about cash management efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.75B	3.82B	17.31B	18.98B	482.32M
Gross Profit	2.21B	3.22B	12.78B	15.12B	-222.04M
EBITDA	-367.10M	1.09B	12.86B	15.73B	-97.89M
Net Income	-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet
Total Assets	22.53B	23.01B	23.28B	15.83B	2.32B
Cash, Cash Equivalents and Short-Term Investments	16.78B	16.55B	14.06B	2.07B	1.35B
Total Debt	254.20M	219.10M	212.20M	301.50M	240.19M
Total Liabilities	3.12B	2.76B	3.22B	3.94B	946.77M
Stockholders Equity	19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow
Free Cash Flow	-244.60M	4.67B	13.21B	735.70M	-98.92M
Operating Cash Flow	207.70M	5.37B	13.58B	889.70M	-13.47M
Investing Cash Flow	-2.08B	-6.95B	-35.30M	-566.10M	-144.85M
Financing Cash Flow	-45.90M	-778.60M	-1.42B	94.20M	894.73M

BioNTech SE Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 115.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 115.31 is above the 20-day moving average (MA) of 110.96, above the 50-day MA of 106.35, and above the 200-day MA of 109.04, indicating a bullish trend. The MACD of 2.05 indicates Negative momentum. The RSI at 63.93 is Neutral, neither overbought nor oversold. The STOCH value of 94.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.

BioNTech SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	72 Outperform	$14.43B	13.14	22.69%	―	25.11%	46.46%
ARGX	70 Outperform	$36.23B	42.62	17.33%	―	78.01%	―
ALNY	66 Neutral	$42.77B	―	-414.62%	―	17.21%	21.16%
BNTX	62 Neutral	$27.72B	―	-3.87%	―	0.58%	-764.64%
SWTX	61 Neutral	$3.54B	―	-51.57%	―	730.42%	31.63%
Sector *	60 Neutral	HK$16.95B	5.65	-7.44%	2.87%	11.55%	-28.15%
MRNA	55 Neutral	$13.15B	―	-29.34%	―	-38.25%	44.29%